Stock A330350 WITHUS PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials WITHUS PHARMACEUTICAL Co.,LTD.

Equities

A330350

KR7330350000

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 15/05/2024 BST 		5-day change 1st Jan Change
8,190 KRW +0.61% Intraday chart for WITHUS PHARMACEUTICAL Co.,LTD. -0.85% -15.83%
2023 WITHUS PHARMACEUTICAL Co.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2020 Withuspharmaceutical Co.,Ltd. has completed an IPO in the amount of KRW 25.44 billion. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 189,477 138,481 123,616 128,366
Enterprise Value (EV) 1 167,261 119,107 118,527 137,174
P/E ratio 17.9 x 32.5 x 49.8 x 16.1 x
Yield - - - -
Capitalization / Revenue 3.55 x 2.41 x 1.91 x 1.6 x
EV / Revenue 3.13 x 2.07 x 1.83 x 1.71 x
EV / EBITDA 18.2 x 18.6 x 17.4 x 12.8 x
EV / FCF 107 x -39.6 x -10.8 x -10.1 x
FCF Yield 0.93% -2.53% -9.23% -9.9%
Price to Book 2.46 x 1.71 x 1.49 x 1.42 x
Nbr of stocks (in thousands) 13,189 13,189 13,193 13,193
Reference price 2 14,367 10,500 9,370 9,730
Announcement Date 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 53,406 57,419 64,680 80,119
EBITDA 1 9,207 6,387 6,826 10,754
EBIT 1 7,230 4,886 4,878 7,909
Operating Margin 13.54% 8.51% 7.54% 9.87%
Earnings before Tax (EBT) 1 7,761 5,240 4,158 9,141
Net income 1 6,652 4,264 2,479 7,959
Net margin 12.46% 7.43% 3.83% 9.93%
EPS 2 804.0 323.3 188.0 603.4
Free Cash Flow 1 1,562 -3,011 -10,942 -13,576
FCF margin 2.93% -5.24% -16.92% -16.95%
FCF Conversion (EBITDA) 16.97% - - -
FCF Conversion (Net income) 23.48% - - -
Dividend per Share - - - -
Announcement Date 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - 8,809
Net Cash position 1 22,216 19,373 5,089 -
Leverage (Debt/EBITDA) - - - 0.8191 x
Free Cash Flow 1 1,562 -3,011 -10,942 -13,576
ROE (net income / shareholders' equity) 12.4% 5.4% 3.02% 9.18%
ROA (Net income/ Total Assets) 6.64% 2.71% 2.56% 3.95%
Assets 1 100,200 157,191 96,926 201,401
Book Value Per Share 2 5,829 6,136 6,295 6,839
Cash Flow per Share 2 1,175 1,049 683.0 695.0
Capex 1 5,264 6,667 15,332 10,807
Capex / Sales 9.86% 11.61% 23.7% 13.49%
Announcement Date 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
WITHUS PHARMACEUTICAL CO.,LTD. Stock WITHUS PHARMACEUTICAL Co.,LTD.
-15.83% 80.27M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.36% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.77% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.60% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.07% 331B
ABBVIE INC. Stock AbbVie Inc.
+6.04% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.77% 239B
NOVARTIS AG Stock Novartis AG
+9.13% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-3.97% 209B
AMGEN INC. Stock Amgen Inc.
+9.27% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A330350 Stock
  4. Financials WITHUS PHARMACEUTICAL Co.,LTD.